Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Oral Anti Diabetic Agents in the Hospital
NCT04416269 · Emory University · PHASE4 · terminated · last registry update 2026-08-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was suspended and during this time recruitment and study activities were halted. The study was ultimately terminated in April 2026 without having re-opened for recruitment additional participants.” | – | Registry record, Emory University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VDR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Results posted on the registry: ProgenaBiome, Hydroxychloroquine (NCT04335084)
- 2026-10-26Phase 3 first posted: Shanghai University of Traditional Chinese Medicine, Quan Duzhong Capsules + Quan Duzhong Capsule Placebo (NCT07895082)
- 2026-10-22Phase 3 first posted: Pathalys Pharma, PLS240 + Standard of Care (NCT07890584)
- 2026-10-21Also stopped (terminated): Jantchou Prevost, vitamin D3 (NCT03999580)
- 2026-10-09Results posted on the registry: Washington University School of Medicine, Denosumab + Placebo (NCT04067726)
- 2026-10-05Results posted on the registry: Vanderbilt University Medical Center, Empiric Therapy: Drug + Selective Therapy: Drug (NCT05365477)
- 2026-10-01Also stopped (terminated): Inozyme Pharma, INZ-701 + Control Arm (Conventional Therapy) (NCT06046820)
- 2026-09-18Phase 3 first posted: Martin Blomberg Jensen, empagliflozin (Jardiance) 25 mg + Losartan 100 mg (NCT07828002)
- 2026-09-08Results posted on the registry: University of Kansas Medical Center, a drug against VDR (NCT03860792)
- 2026-09-03Results posted on the registry: VA Office of Research and Development, Teriparatide or human parathyroid hormone (PTH) 1-34 + Cinacalcet (NCT03994172)
- 2026-08-26Also stopped (terminated): Diamyd Medical AB, Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel® + Placebo (NCT05018585)
- 2026-08-07Results posted on the registry: Brigham and Women's Hospital, a drug against VDR (NCT01728571)
- 2026-08-06Also stopped (terminated): University Hospital, Clermont-Ferrand, Vitamin D (drug) (NCT01893385)
- 2026-08-05Results posted on the registry: University of Rochester, Vitamin D3 (NCT01419730)
- 2026-08-04Also stopped (withdrawn): Abramson Cancer Center at Penn Medicine, Gliolan + Vitamin D3 cholecalciferol) (NCT02698293)
- 2026-07-15Results posted on the registry: Universitas Sebelas Maret, Vitamin D3 + Antiretroviral (ARV) medications (NCT07553052)
- 2026-07-13Results posted on the registry: Texas Christian University, a drug against VDR (NCT07271316)
- 2026-07-10Phase 3 first posted: Johns Hopkins Bloomberg School of Public Health, a drug against VDR (NCT07695883)
- 2026-07-02Results posted on the registry: Sanofi, Doxercalciferol (GZ427397) + Calcitriol (NCT02859896)
- 2026-07-02Also stopped (terminated): Sanofi, Doxercalciferol (GZ427397) + Calcitriol (NCT02859896)
- 2026-06-24Also stopped (terminated): University Hospital, Bordeaux, a drug against VDR (NCT04067219)
- 2026-06-22Phase 3 first posted: Creighton University, doxercalciferol capsules, Hectorol® + Matched Placebo (Capsules) (NCT07660536)
- 2026-06-22Phase 3 first posted: Alexandria University, Calcipotriol 0.005% gel (NCT07658508)
- 2026-06-15Results posted on the registry: University of South Carolina, a drug against VDR (NCT04981847)
- 2026-06-15Results posted on the registry: AbbVie, Paricalcitol (NCT04064827)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision